PATAGONIA: A Global, Multicentre, Phase II Platform Study of Datopotamab Deruxtecan-based Combinations in TROP2 NMR-positive Non-small Cell Lung Cancer
Sponsor: AstraZeneca AB
Phase: 2
Disease: Non-small cell lung cancer, Non-squamous NSCLC
EU trial number: 2025-524836-21-00
Population: Adults ≥18 years (or local age of majority) with unresectable stage IIIB/IIIC or metastatic stage IV non-squamous NSCLC prospectively TROP2 normalized membrane ratio-positive, without actionable genomic alterations including EGFR sensitizing mutations or ALK/ROS1 rearrangements and without prior first-line systemic treatment for advanced disease.
Register Investigator Interest
Interested in offering this trial to suitable patients?